Article Commentary: The Treatment of Thyroid Cancer

Cancer Statistics Review SEER. 1975–2004, National Cancer Institute Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/. Accessed Mar. 3, 2008.

Schlumberger M.J. Papillary and follicular thyroid carcinoma. Review. N Engl J Med 1998; 338: 297–306.

Kazakov V.S. Thyroid cancer after Chernobyl. Nature 1992; 359: 21.

Schneider A.B. Carcinoma of follicular epithelium: Pathogenesis. In: Braverman L.E. , Utiger R.E. , eds. Werner and Ingbar's The Thyroid, 8th Ed. Philadelphia: Lippincott Williams and Wilkins, 2000, pp 875–86.

Sklar C. Abnormalities of the thyroid in survivors of Hodgkin's disease: Data from the childhood cancer survivor study. J Clin Endocrinol Metab 2000; 85: 3227–32.

Rubino C. , Cailleux A.F. , De Vathaire F. Thyroid cancer after radiation exposure. Eur J Cancer 2002; 38: 645–7.

Hundahl S.A. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998; 83: 2638–48.

Tollefsen H.R. , Shah J.P. , Huvos A.G. Hurthle cell carcinoma of the thyroid. Am J Surg 1975; 130: 390–4.

Herrera M.F. , Hay I.D. , Wu P.S. Hurthle cell (oxyphilic) papillary thyroid carcinoma: A variant with more aggressive biologic behavior. World J Surg 1992; 16: 669–75.

Thompsom N.H. , Dunn E.L. , Batsakis J.G. , Nishiyama R.H. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974; 139: 555–60.

Maxwell E.L. , Palme C.E. , Freeman J. Hurthle cell tumors: Applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg 2006; 132: 54–8.

Gharib H. Fine-needle aspiration biopsy of thyroid nodules: Advantages, limitations and effect. Mayo Clin Proc 1994; 69: 44–9.

Mittendorf E.A. , McHenry C.R. Follow-up evaluation and clinical course of patients with benign nodular thyroid disease. Am Surg 1999; 65: 653–8.

Lowhagen T. , Granberg P.O. , Lundell G. Aspiration biopsy cytology in nodules of the thyroid gland suspected to be malignant. Surg Clin North Am 1979; 59: 3–18.

Gharib H. , Goeliner J.R. Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med 1993; 118: 282–9.

Danese D. , Sciacchitano S. , Farsetti A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998; 8: 15–21.

Lin J.D. , Chen S.T. , Chao T.C. Diagnosis and therapeutic strategy for papillary thyroid microcarcinoma. Arch Surg 2005; 140: 940–5.

Mittendorf E.A. , Khiyami A. , McHenry C.R. When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer. Arch Surg 2006; 141: 961–6.

Carmeci C. , Jeffrey R.B. , McDougall I.R. Ultrasound-guided fine needle aspiration biopsy of thyroid masses. Thyroid 1998; 8: 283–9.

Takashima S. , Fukuda H. , Kobayashi T. Thyroid nodules: Clinical effect of ultrasound-guided fine-needle aspiration biopsy. J Clin Ultrasound 1994; 22: 535–42.

Chen H. , Zeiger M.A. , Clark D.P. Papillary carcinoma of the thyroid: Can operative management be based solely on fine-needle aspiration? J Am Coll Surg 1997; 184: 605–10.

Sclabas G.M. , Staerkel G.A. , Shapiro S.E. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 2003; 186: 702–10.

Chow S.M. , Law S.C. , Au S.K. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: Experience in a single institute in Hong Kong, 1960–2000. Clin Oncol 2003; 15: 329–36.

Rosen I. , Azadian A. , Walfish P. Ultrasound-guided fine-needle aspiration biopsy in the management of thyroid disease. Am J Surg 1995; 166: 346–9.

Burguera B. , Gharib H. Thyroid incidentalomas: Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 2000; 29: 187–203.

Papini E. , Guglielmi R. , Bianchini A. Risk of malignancy in nonpalpable thyroid nodules: Predictive value of ultrasound and color-doppler features. J Clin Endocrinol Metab 2002; 87: 1941–6.

Mortensen J.D. , Woolner L.B. , Bennett W.A. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1995; 15: 1270–80.

Neuhold N. , Kaiser H. , Kaserer K. Latent carcinoma of the thyroid in Austria; a systemic autopsy study. Endocr Pathol 2001; 12: 23–31.

Ottino A. , Pianzola H.M. , Castelletto R.H. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989; 64: 547–51.

Yamamoto Y. , Maeda T. , Izumi K. , Otsuka H. Occult papillary carcinoma of the thyroid: A study of 408 autopsy cases. Cancer 1990; 65: 1173–9.

Pellegritti G. , Scolio C. , Lumera G. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: Study of 299 cases. J Clin Endocrinol Metab 2004; 89: 3713–20.

Ito Y. , Uruno T. , Nakamo K. An observational trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13: 381–7.

Shah J.P. , Kian K. , Forastiere A. American Joint Committee on Cancer. Cancer Staging Manual, 6th Ed. New York: Springer-Verlag, 2002, pp 77–87.

Cady B. , Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104: 947–53.

Cady B. , Rossi R. , Silverman M. Further evidence of the validity of risk group definition in differentiated thyroid carcinoma. Surgery 1985; 98: 1171–8.

Hay I.D. , Bergstralh E.J. , Goellner J.R. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050–7.

Hermanek P. , Sobin L.H. TNM classification of malignant tumors. In: UICC, International Union Against Cancer. Manual of Clinical Oncology, 4th Ed. Berlin: Springer-Verlag, 1987, p 79.

Loh K.C. , Greenspan F.S. , Gee L. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553–62.

Jukkola A. , Bloigu R. , Ebeling T. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004; 11: 571–9.

Gagel R.F. , Goepfert H. , Callender D.L. Changing concepts in the pathogenesis and management of thyroid carcinoma. CA Cancer J Clin 1996; 46: 261–83.

Dean D.S. , Hay I.D. Prognostic indicators in differentiated thyroid cancer. Cancer Control 2000; 7: 229–39.

Sanders L.E. , Cady B. Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133: 419–25.

Lo C.Y. , Chan W.F. , Lam K.Y. Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg 2004; 28: 1103–9.

Wanebo H. , Coburn M. , Teates D. , Cole B. Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer. Ann Surg 1998; 227: 912–21.

Kim S. , Wei J.P. , Braveman J.M. , Brams D.M. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004; 139: 390–4.

Lundgren C.I. , Hall P. , Dickman P.W. , Zenenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg 2007; 94: 571–7.

Clark O.H. Total thyroidectomy: The treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982; 196: 361–70.

Wada N. , Duh Q.Y. , Sugino K. Lymph node metastasis from 259 papillary thyroid microcarcinomas: Frequency, pattern of occurrence and recurrence and optimal strategy for neck dissection. Ann Surg 2003; 237: 399–407.

Shindo M. , Wu J.C. , Park E.E. , Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 650–4.

Falvo L. , Catania A. , Grilli P. Treatment of “locally advanced” well-differentiated thyroid carcinomas. Ann Ital Chir 2004; 75: 17–21.

McCaffrey T.V. , Bergstralh E.J. , Hay I.D. Locally invasive papillary thyroid carcinoma: 1940–1990. Head Neck 1994; 16: 165–72.

Patel K.N. , Shaha A.R. Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 112–6.

Gillenwater A.M. , Geopfert H. Surgical management of laryngotracheal and esophageal involvement by locally advanced thyroid cancer. Semin Surg Oncol 1999; 16: 19–29.

Wang W. , Macapinlac H. , Larson S.M. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291–302.

Larson S.M. , Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002; 37: 169–74.

Kim T.H. , Yang D.S. , Jung K.Y. Value of external irradiation for locally advanced papillary thyroid cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1006–12.

Philips P. , Hanzen C. , Andry G. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993; 19: 399–404.

Palme C.E. , Waseem Z. , Raza N. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 819–24.

Harris P.E. The management of thyroid cancer in adults: A review of new guidelines. Clinical Medicine. Royal College of Physicians 2002; 2: 144–6.

Castro M.R. , Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142: 926–31.

Eng C. , Clayton D. , Schuffenecker I. , Lenoir G. The relationship between specific RET proto-oncogene mutation and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996; 276: 1575–9.

Decker R.A. , Peacock M.L. Update on the profile of multiple endocrine neoplasia type 2a RET mutations: Practical issues and implications for genetic testing. Cancer Suppl 1997; 80: 557–68.

Elisei R. , Bottici V. , Luchetti F. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endo Metab 2004; 89: 163–8.

Singer P.A. , Cooper D.S. , Daniels G.H. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 156: 2165–72.

Dulgeroff A.J. , Hershman J.M. Medical therapy for differentiated thyroid carcinoma. Endocrinol Rev 1994; 15: 500–15.

Degroot L.J. , Kaplan E.L. , McMormick M. , Strauss F.H. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414–24.

Hay I.D. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19: 545–76.

Mazzaferri E.L. , Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–28.

Mazzaferri E.L. , Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. Review. J Clin Endocrinol Metab 2001; 86: 1447–63.

Lundgren C.I. , Hall P. , Dickman P.W. , Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg 2007; 94: 571–7.

Sawka A.M. , Kullathorn T. , Brouwers M. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endorinol Metab 2004; 89: 3668–76.

Schlumberger M. , Challenton C. , DeVathaire F. Radioactive iodine treatment and external radiotherapy for lung and bone metastasis from thyroid carcinoma. J Nucl Med 1996; 37: 598–605.

Ashcraft M.W. , van Herle A.J. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 1981; 71: 806–14.

Lin J.D. , Huang M.J. , Hsu B.R. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002; 80: 45–51.

Ozata M. , Suzuki S. , Miyamoto T. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98–105.

Barsano C.P. , Skosey C. , DeGroot L.J. , Refetoff S. Serum thyroglobulin in the management of patients with thyroid cancer. Arch Intern Med 1982; 142: 763–7.

Pacini S.I. , Lari R. , Mazzeo S. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985; 23: 405–11.

Shlumberger M. , Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998; 138: 249–52.

Baudin E. , Do Cao C. , Cailleux A.F. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88: 1107–11.

Kinder B.K. Well differentiated thyroid cancer. Current Opinion in Onc 2003; 15: 71–7.

Fagin J.A. Perspective: Lessons learned from molecular genetic studies of thyroid cancer: Insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 2002; 143: 2025–8.

Kroll T.G. , Sarraf P. , Pecciarini L. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000; 289: 1357–60.

McDougall I.R. , Weigel R.J. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opinion in Onc 2001; 13: 39–43.

Pacini F. , Molinaro E. , Lippi F. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 5686–90.

Mazzaferri E.L. , Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endo-crinol Metab 2002; 87: 1490–8.

Giovanni V. , Arianna L.G. , Antonio C. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: Experience from a large patient cohort in a single center. Clin Endocrinol (Oxf) 2002; 56: 247–52.

Frilling A. , Tecklenborg K. , Gorges R. Preoperative diagnostic value of [18F] Fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234: 804–11.

Lencioni R. , Cioni D. , Corcetti L. Percutaneous ablation of hepatocellular carcinoma. Sate of the Art Liver Transpl 2004; 10(supp): 91–7.

Monchik J.M. , Donatini G. , Iannuccilli J. , Dupuy D.E. Radio-frequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006; 244: 296–304.

Dupuy D.E. , Monchik J.M. Radiofrequency ablation of recurrent thyroid cancer. In: Ellis L.M. , Curley S.A. , Tanabe eds. Textbook Radiofrequency Ablation of Cancer. New York: Springer-Verlag, 2003, pp 213–223.

Dupuy D.E. , Monchik J.M. , Decrea C. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001; 130: 371–7.

Pacini F. Role of percutaneous ethanol injection in management of nodular lesions of the thyroid gland. J Nuc Med 2003; 44: 211–2.

Charboneau J.W. , Hay I.D. , van Heerden J.A. Persistent primary hyperparathyroidism: Successful ultrasound-guided percutaneous ethanol ablations of an occult adenoma. Mayo Clin Proc 1988; 63: 913–7.